2 / 7
Page 19
Notes:
conference
series
.com
Volume 7, Issue 4 (Suppl)
J Biotechnol Biomater, an open access journal
ISSN: 2155-952X
Bio America 2017
October 19-20, 2017
October 19-20, 2017 | New York, USA
18
th
Biotechnology Congress
Hormone-immunotherapy in endocrine-dependent metastatic breast cancer and serum biomarkers
H
ormone therapy is currently advised for ER+ metastatic breast cancer patients; however in most of them the arising
of resistance is a not yet well understood hurdle to overcome. We hypothesized that in these patients during clinical
benefit from antiestrogen therapy the addition of cycles of sequential immunotherapy could prolong the benefit and delay
the occurrence of acquired hormone resistance. In order to validate this hypothesis, in 1992 we started an open, prospective
exploratory clinical trial. Here we summarize and update the clinical data and focus on the main serum biomarkers that proved
helpful to monitor the efficacy of hormone immune therapy.
Biography
Andrea Nicolini mainly devoted his research over the past 20 years to the field of breast and colorectal cancer, particularly the use of serum tumor markers in the
"early" detection and treatment of metastatic disease and the function of cell mediated immunity. The role of immunotherapy combined with conventional antiestro-
gen therapy to overcome the arising of resistance in endocrine dependent metastatic breast cancer was another main explored research field. He has published
about 250 original papers/review articles (including book chapters), most of them in peer reviewed journals with I F. He is a part of the Editorial Board of a few high
rank scientific journals and regularly serves as reviewer for them and many others.
andrea.nicolini@med.unipi.itAndrea Nicolini
Pisa University, Italy
Andrea Nicolini, J Biotechnol Biomater 2017, 7:4 (Suppl)
DOI: 10.4172/2155-952X-C1-078